OmniAb

OmniAb licenses antibody discovery technology to pharmaceutical, biotech, and academic partners, using engineered transgenic animals (OmniRat, OmniChicken, OmniMouse), bispecific platforms (OmniFlic, OmniClic), cow-inspired OmniTaur antibodies, the OmnidAb single-domain platform, and the OmniDeep suite of in-silico AI/ML discovery tools. Spun out of Ligand Pharmaceuticals in 2022 and headquartered in Emeryville, California, the company generates revenue through partnered milestone payments and license fees; Q2 2026 revenue more than tripled year over year as partner milestones accelerated, and it raised its full-year 2026 revenue and year-end cash outlook.